Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683

Expert Opinion on Biological Therapy

Volumn 16, Issue 10, 2016, Pages 1311-1312

  Gentileschi, Stefano ^a   Barreca, Cristiana ^a   Bellisai, Francesca ^a   Biasi, Giovanni ^a   Brizi, Maria Giuseppina ^a   De Stefano, Renato ^a   Fabbroni, Marta ^a   Fioravanti, Antonella ^a   Frati, Elena ^a   Selvi, Enrico ^a   Vitale, Antonio ^a   Cantarini, Luca ^a   Frediani, Bruno ^a   Galeazzi, Mauro ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CORTICOSTEROID; CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; CT-P13; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; BEHCET DISEASE; CLINICAL EFFECTIVENESS; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; HUMAN; IMMUNOGENICITY; LETTER; OBSERVATIONAL STUDY; PATIENT-REPORTED OUTCOME; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RELAPSE; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; TREATMENT RESPONSE; UVEITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLIXIMAB; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 84976339013     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1198765     Document Type: Letter

References (4)

1. E.Nikiphorou, H.Kautiainen, P.Hannonen, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. doi:10.1517/14712598.2015.1103733.•• To date, this is the only indipendent prospective observational study about the issue of switching between Remicade and its biosimilar, CT-P13.
2. D.H.Yoo, P.Hrycaj, P.Miranda, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. doi:10.1136/annrheumdis-2012-203090.
3. W.Park, P.Hrycaj, S.Jeka, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis:the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. doi:10.1136/annrheumdis-2012-203091.
4. W.Park, D.H.Yoo, J.Jaworski, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis:54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. doi:10.1186/s13075-016-0930-4.